HF
CTNM

HRT Financial’s Contineum Therapeutics CTNM Stock Holding History

HRT Financial’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$289K Buy
+22,170
New +$297K ﹤0.01% 2907
2024
Q4 		– Sell
-11,142
Closed -$213K – 3395
2024
Q3 		$213K Buy
+11,142
New +$214K ﹤0.01% 1949

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HRT Financial's CTNM Position: Q1 2026 in Review

HRT Financial opened a new position in Contineum Therapeutics (CTNM) in Q1 2026: 22,170 shares worth $289K. The stake represents ﹤0.01% of the portfolio and ranks #2907 among its holdings. This is a return to the name: HRT Financial previously reported a position in CTNM as recently as Q3 2024.

HRT Financial first reported a position in CTNM in Q3 2024 and has held it in 2 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • HRT Financial held 22,170 shares of Contineum Therapeutics worth $289K as of Q1 2026.
  • Contineum Therapeutics was a new HRT Financial position in Q1 2026.
  • Contineum Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #2907 holding.
  • HRT Financial first reported a position in Contineum Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.